Friday, October 02, 2020 9:32:24 PM
Today's Science magazine, the house organ of AAAS, the American Association for the Advancement of Science, highlights the problem of neurodegeneration.
In the second paragraph in the lead article, it is stated, "Much fundamental research has led to a greater understanding of the pathophysiological processes involved in neurodegeneration and has revealed that accumulation of misfolded, toxic proteins is frequently a cause of neurodegeneration."
The "accumulation of misfolded, toxic proteins is frequently a cause of neurodegeneration." Will the Anavex sigma-1 receptor agonists treat or prevent protein misfolding? Strong evidence that they do, by optimizing the biochemical processes in endoplasmic reticula, the cellular location of protein folding.
An article made this claim: "Disrupted sleep often occurs before or in the early stages of neurogenerative disease. An important function of sleep is to allow waste products — including misfolded proteins associated with neurodegeneration — to be cleared from the brain via the glymphatic system."
It is noted that improved sleep has been a clinical outcome of those taking blarcamesine in early clinical trials.
The article elaborates on the crucial importance of functional autophagy, the ability of neurons to collect and reprocess waste proteins. Facilitated, optimized autophagy has been noted with blarcamesine.
Note the diseases referred to in this statement: "In addition to the deterioration of sleep architecture in aging, the neurodegenerative diseases — including AD, Parkinson’s disease, Huntington’s disease, the multisystem atrophies, and the FTDs — are all associated with sleep disturbances." Anavex is targeting AD (Alzheimer's disease), a form of Parkinson's disease, and FTD, frontotemporal dementia.
It will be an error to discount or dismiss the ability of blarcamesine to improve sleep.
The issue has many pages discussing the aggregation of the pathogenic proteins of Parkinson's disease, Alzheimer's disease, and other CNS diseases. Doubtless, the aggregation of these proteins cause their associated diseases. But I didn't find any discussion of how neurons might be treated so as to prevent waste protein aggregation. That's where blarcamesine will come into play, with it's ability of facilitate and promote normalized sigma-1 receptor protein functions; which include proper folding of proteins (enzymes) that clear waste proteins in earlier, more healthy stages of life.
An article deliberated on the genetics of Alzheimer's disease. But I note that except in some rather rare forms of Alzheimer's, the disease is late-onset. Until late middle age or later, even with "bad genes," the disease is not present. Can blarcamesine maintain a more youthful, functional status in nerves, preventing the geriatric onset of the disease? Let's see how the Alzheimer's clinical trial turns out.
In a few years, I expect another issue of Science to be devoted to neurodegeneration: "Sigma-1 Receptor Activation Terminates Neurodegeneration."
Recent AVXL News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- The Gross Law Firm Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 03/22/2024 09:45:00 AM
- Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia • GlobeNewswire Inc. • 03/18/2024 11:30:00 AM
- Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference • GlobeNewswire Inc. • 02/26/2024 12:30:00 PM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM